Date: 2015-01-15
Type of information: Production agreement
Compound: therapeutic monoclonal antibodies
Company: Sanofi (France) Boehringer Ingelheim (Germany)
Therapeutic area:
Type agreement: production maufacturing
Action mechanism:
Disease:
Details: * On January 15, 2015, Sanofi announced it has entered into a strategic agreement with Boehringer Ingelheim for the manufacture of therapeutic monoclonal antibodies to reinforce Sanofi’s manufacturing capacity to support upcoming product launches. Today, 72 percent of Sanofi’s Research and Development projects are in biologics, nearly half of which are monoclonal antibodies (mAbs). Under the terms of the agreement, Sanofi will have access to Boehringer Ingelheim’s capabilities in Biberach an der Riss, Germany to transfer and manufacture therapeutic mAbs. Initial product transfers will begin in early 2015.
Financial terms: Financial terms were not disclosed.
Latest news:
